Vulvovaginal Pyoderma Gangrenosum in a Patient Treated With Ocrelizumab for Multiple Sclerosis

Alyssa N. Breneman; Ariel E. Eber; Hoosna Haque; Libby Levine; Anca Askanase; Claire S. Riley; Miriam Keltz Pomeranz; Dahlia Hassan; Silvia E. Mancebo; Melanie Polin; Alexander Melamed; Lindsey A. Bordone; Mary Rosser; Allison Gockley; Stephanie M. Gallitano

doi:10.1097/LGT.0000000000000661

Vulvovaginal Pyoderma Gangrenosum in a Patient Treated With Ocrelizumab for Multiple Sclerosis

Alyssa N. Breneman
, Ariel E. Eber
, Hoosna Haque
, Libby Levine
, Anca Askanase
, Claire S. Riley
, Miriam Keltz Pomeranz
, Dahlia Hassan
, Silvia E. Mancebo
, Melanie Polin
, Alexander Melamed
, Lindsey A. Bordone
, Mary Rosser
, Allison Gockley
, Stephanie M. Gallitano

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Ocrelizumab is an anti-CD20 monoclonal antibody treatment for multiple sclerosis (MS).1 Pyoderma gangrenosum (PG) is an inflammatory, ulcerative dermatosis.2 Vulvovaginal PG has rarely been associated with rituximab, another anti-CD20 monoclonal antibody.2 We report a unique case of ocrelizumab-associated vulvovaginal PG.

Original language	English (US)
Pages (from-to)	189-191
Number of pages	3
Journal	Journal of lower genital tract disease
Volume	26
Issue number	2
DOIs	https://doi.org/10.1097/LGT.0000000000000661
State	Published - Apr 1 2022
Externally published	Yes

Keywords

intravenous immunoglobulin
ocrelizumab
pyoderma gangrenosum
rituximab
side effect
vulvovaginal

ASJC Scopus subject areas

Obstetrics and Gynecology

Access to Document

10.1097/LGT.0000000000000661

Cite this

Breneman, A. N., Eber, A. E., Haque, H., Levine, L., Askanase, A., Riley, C. S., Pomeranz, M. K., Hassan, D., Mancebo, S. E., Polin, M., Melamed, A., Bordone, L. A., Rosser, M., Gockley, A., & Gallitano, S. M. (2022). Vulvovaginal Pyoderma Gangrenosum in a Patient Treated With Ocrelizumab for Multiple Sclerosis. Journal of lower genital tract disease, 26(2), 189-191. https://doi.org/10.1097/LGT.0000000000000661

Breneman, AN, Eber, AE, Haque, H, Levine, L, Askanase, A, Riley, CS, Pomeranz, MK, Hassan, D, Mancebo, SE, Polin, M, Melamed, A, Bordone, LA, Rosser, M, Gockley, A & Gallitano, SM 2022, 'Vulvovaginal Pyoderma Gangrenosum in a Patient Treated With Ocrelizumab for Multiple Sclerosis', Journal of lower genital tract disease, vol. 26, no. 2, pp. 189-191. https://doi.org/10.1097/LGT.0000000000000661

@article{95867a1bdbdc48f0925a1c12edaa6fd1,

title = "Vulvovaginal Pyoderma Gangrenosum in a Patient Treated With Ocrelizumab for Multiple Sclerosis",

abstract = "Ocrelizumab is an anti-CD20 monoclonal antibody treatment for multiple sclerosis (MS).1 Pyoderma gangrenosum (PG) is an inflammatory, ulcerative dermatosis.2 Vulvovaginal PG has rarely been associated with rituximab, another anti-CD20 monoclonal antibody.2 We report a unique case of ocrelizumab-associated vulvovaginal PG.",

keywords = "intravenous immunoglobulin, ocrelizumab, pyoderma gangrenosum, rituximab, side effect, vulvovaginal",

author = "Breneman, \{Alyssa N.\} and Eber, \{Ariel E.\} and Hoosna Haque and Libby Levine and Anca Askanase and Riley, \{Claire S.\} and Pomeranz, \{Miriam Keltz\} and Dahlia Hassan and Mancebo, \{Silvia E.\} and Melanie Polin and Alexander Melamed and Bordone, \{Lindsey A.\} and Mary Rosser and Allison Gockley and Gallitano, \{Stephanie M.\}",

note = "Publisher Copyright: Copyright {\textcopyright} 2022 ASCCP.",

year = "2022",

month = apr,

day = "1",

doi = "10.1097/LGT.0000000000000661",

language = "English (US)",

volume = "26",

pages = "189--191",

journal = "Journal of lower genital tract disease",

issn = "1089-2591",

publisher = "Lippincott Williams and Wilkins",

number = "2",

}

TY - JOUR

T1 - Vulvovaginal Pyoderma Gangrenosum in a Patient Treated With Ocrelizumab for Multiple Sclerosis

AU - Breneman, Alyssa N.

AU - Eber, Ariel E.

AU - Haque, Hoosna

AU - Levine, Libby

AU - Askanase, Anca

AU - Riley, Claire S.

AU - Pomeranz, Miriam Keltz

AU - Hassan, Dahlia

AU - Mancebo, Silvia E.

AU - Polin, Melanie

AU - Melamed, Alexander

AU - Bordone, Lindsey A.

AU - Rosser, Mary

AU - Gockley, Allison

AU - Gallitano, Stephanie M.

PY - 2022/4/1

Y1 - 2022/4/1

N2 - Ocrelizumab is an anti-CD20 monoclonal antibody treatment for multiple sclerosis (MS).1 Pyoderma gangrenosum (PG) is an inflammatory, ulcerative dermatosis.2 Vulvovaginal PG has rarely been associated with rituximab, another anti-CD20 monoclonal antibody.2 We report a unique case of ocrelizumab-associated vulvovaginal PG.

AB - Ocrelizumab is an anti-CD20 monoclonal antibody treatment for multiple sclerosis (MS).1 Pyoderma gangrenosum (PG) is an inflammatory, ulcerative dermatosis.2 Vulvovaginal PG has rarely been associated with rituximab, another anti-CD20 monoclonal antibody.2 We report a unique case of ocrelizumab-associated vulvovaginal PG.

KW - intravenous immunoglobulin

KW - ocrelizumab

KW - pyoderma gangrenosum

KW - rituximab

KW - side effect

KW - vulvovaginal

UR - https://www.scopus.com/pages/publications/85128000053

UR - https://www.scopus.com/pages/publications/85128000053#tab=citedBy

U2 - 10.1097/LGT.0000000000000661

DO - 10.1097/LGT.0000000000000661

M3 - Article

C2 - 35256568

AN - SCOPUS:85128000053

SN - 1089-2591

VL - 26

SP - 189

EP - 191

JO - Journal of lower genital tract disease

JF - Journal of lower genital tract disease

IS - 2

ER -

Vulvovaginal Pyoderma Gangrenosum in a Patient Treated With Ocrelizumab for Multiple Sclerosis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this